BMY - Bristol-Myers Squibb

-

$undefined

N/A

(N/A)

Bristol-Myers Squibb NYSE:BMY Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Location: Route 206 & Province Line Road, Princeton, NJ, 08543, United States | Website: https://www.bms.com | Industry: Drug Manufacturers - General | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

136.9B

Cash

11.78B

Avg Qtr Burn

N/A

Short % of Float

1.82%

Insider Ownership

0.08%

Institutional Own.

82.21%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Breyanzi® (lisocabtagene maraleucel) Details
Chronic lymphocytic leukemia, Blood cancer, Small lymphocytic lymphoma

Approved

Quarterly sales

KRAZATI (Adagrasib) + Cetuximab Details
Cancer, Colorectal cancer , Solid tumor/s

Approved

Quarterly sales

Zeposia (ozanimod) Details
Multiple sclerosis, Ulcerative colitis

Approved

Quarterly sales

Approved

Quarterly sales

Opdivo® (nivolumab) + chemotherapy Details
Cancer, Non-small cell lung carcinoma

Approved

Quarterly sales

KRAZATI (Adagrasib) Details
Cancer, Lung cancer, Non-small cell lung carcinoma, Solid tumor/s, Colorectal cancer

Approved

Quarterly sales

Sotyktu (deucravacitinib) Details
Psoriasis, Skin disease/disorder

Approved

Quarterly sales

Augtyro™ (Repotrectinib) Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Camzyos®(mavacamten) Details
Hypertrophic cardiomyopathies

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Eliquis Details
Stroke, Atrial fibrillation, Blood clots

Approved

Quarterly sales

Approved

Quarterly sales

Reblozyl®(luspatercept-aamt) Details
Cancer, Anemia, Blood cancer, Mutant Myelodysplastic Syndromes

Approved

Quarterly sales

Approved

Quarterly sales

OPDIVO (nivolumab) injection Details
Gastric cancer, Gastroesophageal adenocarcinomas

PDUFA

Approval decision

BMS-986278 [(LPA1) antagonist] Details
Lung disease, Idiopathic pulmonary fibrosis

Phase 3

Data readout

Milvexian Details
Acute coronary syndrome, Stroke, Atrial fibrillation

Phase 3

Data readout

KarXT (M1/M4 muscarinic agonist) Details
Schizophrenia, Mental health, Alzheimer's disease

Phase 3

Data readout

Opdivo® (nivolumab) + Yervoy (ipilimumab) Details
Non-small cell lung carcinoma, Cancer

Phase 3

Update

Phase 3

Update

Phase 3

Update

Phase 3

Update

KRAZATI (Adagrasib) Details
Non-small cell lung carcinoma, Cancer, Lung cancer, Solid tumor/s

Phase 3

Update

Adagrasib (KRAZATI®) + Cetuximab Details
Solid tumor/s, Colorectal cancer , Cancer

Phase 3

Update

Phase 3

Update

Phase 3

Update

Opdivo® (nivolumab) + Yervoy (ipilimumab) Details
Non-small cell lung carcinoma, Cancer

Phase 3

Update

Adagrasib (KRAZATI®) + Pembrolizumab Details
Lung cancer, Cancer, Non-small cell lung carcinoma, Solid tumor/s

Phase 3

Update

A/I CELMoD (CC-99282) Details
Relapsed/ refractory lymphoma, Non-Hodgkin lymphoma, Cancer

Phase 2

Interim update

Phase 2

Initiation

Phase 1/2

Data readout

Phase 1/2

Data readout

Golcadomide (CELMoD™ Agent) +rituximab Details
Blood cancer, Diffuse large B cell lymphoma, Non-Hodgkin lymphoma

Phase 1/2

Update

MRTX1133 Details
Cancer, Solid tumor/s, Colorectal cancer , Pancreatic cancer, Lung cancer

Phase 1/2

Update

Adagrasib (KRAZATI®) + VS-6766 Details
Lung cancer, Cancer, Non-small cell lung carcinoma, Solid tumor/s

Phase 1/2

Initiation

Golcadomide (CELMoD™ Agent) Details
Blood cancer, Non-Hodgkin lymphoma

Phase 1b

Update

Phase 1b

Update

KAR-2618 Details
Mental health, Major depressive disorder

Phase 1b

Initiation

BMS-986393/CC-95266 Details
High Refractory Multiple Myeloma

Phase 1

Update

BMS-986365 (CC-94676) Details
Castration-resistant prostate cancer

Phase 1

Update